ReviewJournal of the Society for Cardiovascular Angiography & Interventions
PCI in Patients With Heart Failure: Current Evidence, Impact of Complete Revascularization, and Contemporary Techniques to Improve Outcomes.
Review in Journal of the Society for Cardiovascular Angiography & Interventions. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Characteristics and Outcomes of Older Patients Undergoing Protected Percutaneous Coronary Intervention With Impella.Journal of the American Heart Association · 2025Trial
- Beta-blockers after myocardial infarction with preserved ejection fraction-reexamining established paradigms?Journal of thoracic disease · 2026Article
- Association Between Optimal Revascularization for Chronic Total Occlusion and Long-Term Outcomes in Patients With Heart Failure With or Without Type 2 Diabetes.Journal of the American Heart Association · 2026Article
- Article
- The effects of Traditional Chinese Medicine on cardiac function after percutaneous coronary intervention: a meta-analysis and systematic review.Frontiers in cardiovascular medicine · 2026Review
- Navigating high-risk PCI with axillary impella support: a case report.Annals of medicine and surgery (2012) · 2025Article
- Dapagliflozin combined with sacubitril/valsartan promotes cardiac function recovery in elderly patients with acute myocardial infarction.American journal of translational research · 2025Article
- Association Between Revascularization and 30-Day Survival of Ischemic Cardiomyopathy Patients in Dr. Hasan Sadikin General Hospital.Vascular health and risk management · 2025Observational
- Protective effects of crocin against contrast induced acute kidney injury following angiography: A randomized controlled clinical trial.ARYA atherosclerosis · 2025Article
- Intravascular Ultrasound Guiding Percutaneous Coronary Interventions in Complex Higher Risk-Indicated Patients (CHIPs): Insight from Clinical Evidence.Reviews in cardiovascular medicine · 2024Review
- A Novel Approach to Identifying Hibernating Myocardium Using Radiomics-Based Machine Learning.Cureus · 2024Article
- Mortality rate after coronary revascularization in heart failure patients with coronary artery disease.ESC heart failure · 2023Observational
- Myocardial Viability Testing in the Management of Ischemic Heart Failure.Life (Basel, Switzerland) · 2022Review
- Current Landscape and Future Directions of Coronary Revascularization in Ischemic Systolic Heart Failure: A Review.Journal of the Society for Cardiovascular Angiography & InterventionsReview
- Percutaneous Coronary Intervention in Heart Failure: Knowledge Gaps and Opportunities.Journal of the Society for Cardiovascular Angiography & InterventionsArticle
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary artery disease (CAD) is the most common cause of left ventricular systolic dysfunction (LVSD) and heart failure (HF). Revascularization with coronary artery bypass grafting (CABG) reduces all-cause mortality compared with medical therapy alone for these patients. Despite this, CABG is performed in a minority of patients with HF, partly due to patient unwillingness or inability to undergo major cardiac surgery and partly due to physician reluctance to refer for surgery due to high operative risk. Percutaneous coronary intervention (PCI) is a less-invasive method of revascularization that has the potential to reduce periprocedural complications compared with CABG in patients with HF. Recent advances in PCI technology and technique have made it realistic to achieve more complete revascularization with PCI in high-risk patients with HF, although no randomized controlled clinical trials (RCTs) of PCI in HF compared with either medical therapy or CABG have been performed. In this review, we discuss the currently available evidence for PCI in HF and the association between the extent of revascularization and clinical outcomes in HF. We also review recent advances in PCI technology and techniques with the potential to improve clinical outcomes in HF. Finally, we discuss emerging clinical trial evidence of revascularization in HF and the large, persistent evidence gaps that should be addressed with future clinical trials of revascularization in HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.